Jane E. Ambler

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae

Xiao-Su Pan, Jane E. Ambler, Shaheen Mehtar et al. · Antimicrobial Agents and Chemotherapy · 1996 · 438 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17

Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro

Victoria J. Heaton, Jane E. Ambler, L. Mark Fisher · Antimicrobial Agents and Chemotherapy · 2000 · 82 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Exebacase in Addition to Standard-of-Care Antibiotics for <i>Staphylococcus aureus</i> Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)

Vance G. Fowler, Anita Das, Joy Lipka-Diamond et al. · Clinical Infectious Diseases · 2024 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for<i>Staphylococcus aureus</i>: the role of PBP2a in the activity of ceftaroline

Sushmita D. Lahiri, Robert E. McLaughlin, James Whiteaker et al. · Journal of Antimicrobial Chemotherapy · 2015 · 45 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> : Evidence That <i>gyrA</i> Mutations Arise at a Lower Rate and That Mutation in <i>gyrA</i> or <i>parC</i> Predisposes to Further Mutation

Stephen H. Gillespie, LeRoy L. Voelker, Jane E. Ambler et al. · Microbial Drug Resistance · 2003 · 44 citations

Life Sciences, Infectious Diseases, Microbiology +17